Literature DB >> 10624848

Definitive radiotherapy for 114 cases of T3N0 glottic carcinoma: influence of dose-volume parameters on outcome.

J P Wylie1, M Sen, R Swindell, A J Sykes, W T Farrington, N J Slevin.   

Abstract

BACKGROUND AND
PURPOSE: Assuming that the dose-response curve for T3N0M0 glottic carcinoma is steep and that the rate of occult lymph node metastases is low, it should be possible to employ high biological tumour doses to modest target volumes and thereby maximise laryngeal control without compromising final neck control. Within the constraints of a retrospective study we aim to examine this policy with respect to local control, incidence of nodal relapse and late complications.
MATERIALS AND METHODS: One hundred and fourteen patients with T3N0M0 glottic carcinoma who received a 3-week schedule of radical radiotherapy between 1986 and 1994 were analysed. The median age was 67 years (range, 34-85 years) and the median follow-up for living patients was 4.8 years (1.9-8.9 years). There were no strict selection criteria for those patients treated with radiotherapy.
RESULTS: The 5-year overall survival was 54%. The 5-year local control with radiotherapy and the ultimate loco-regional control following salvage laryngectomy were 68 and 80%, respectively. Nine patients (8%) suffered a regional nodal relapse but only three of these (3% overall) occurred in the absence of local failure. Four patients (3.5%) developed serious late complications requiring surgical intervention (three received 55 Gy and one 52.5 Gy).
CONCLUSIONS: It is possible to employ maximum tolerable doses to specific target volumes and thereby exploit the dose response demonstrated and minimise major late effects. The use of modest target volumes resulted in only 3% of patients requiring surgery that might have been avoided had prophylactic neck irradiation been employed.

Entities:  

Mesh:

Year:  1999        PMID: 10624848     DOI: 10.1016/s0167-8140(99)00131-0

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  7 in total

1.  Recent advances in management of laryngeal cancer.

Authors:  Youn Sang Shim
Journal:  Cancer Res Treat       Date:  2004-02-29       Impact factor: 4.679

Review 2.  Preservation of form and function during management of cancer of the larynx and hypopharynx.

Authors:  Jean Louis Lefebvre; Eric Lartigau
Journal:  World J Surg       Date:  2003-07       Impact factor: 3.352

3.  Functional organ preservation in laryngeal and hypopharyngeal cancer.

Authors:  Petra Ambrosch; Asita Fazel
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-04-26

4.  Conventional fractionation should not be the standard of care for T2 glottic cancer.

Authors:  Lynne M Dixon; Catriona M Douglas; Shazril Imran Shaukat; Kate Garcez; Lip Wai Lee; Andrew J Sykes; David Thomson; Nicholas J Slevin
Journal:  Radiat Oncol       Date:  2017-11-14       Impact factor: 3.481

5.  Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.

Authors:  Shao Hui Huang; Brian O'Sullivan; Jie Su; Jolie Ringash; Scott V Bratman; John Kim; Ali Hosni; Andrew Bayley; John Cho; Meredith Giuliani; Andrew Hope; Anna Spreafico; Aaron R Hansen; Lillian L Siu; Ralph Gilbert; Jonathan C Irish; David Goldstein; John de Almeida; Li Tong; Wei Xu; John Waldron
Journal:  Cancer       Date:  2020-06-01       Impact factor: 6.860

6.  Radiotherapy for locally advanced resectable T3-T4 laryngeal cancer-does laryngeal preservation strategy compromise survival?

Authors:  Hideya Yamazaki; Gen Suzuki; Satoaki Nakamura; Shigeru Hirano; Ken Yoshida; Koji Konishi; Teruki Teshima; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2018-01-01       Impact factor: 2.724

Review 7.  Radiotherapy for laryngeal cancer-technical aspects and alternate fractionation.

Authors:  Hideya Yamazaki; Gen Suzuki; Satoaki Nakamura; Ken Yoshida; Koji Konishi; Teruki Teshima; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2017-07-01       Impact factor: 2.724

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.